Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study. Authors' reply-Reference-Cited by-同舟云学术

Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study. Authors' reply

Published:2023-08-10 Issue:5 Volume:58 Page:550-551
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Hsu Yao‐Chun¹²³^ORCID,Wu Chun‐Ying³⁴

Affiliation:

1. Center for Liver Diseases E‐Da Hospital Kaohsiung Taiwan

2. School of Medicine I‐Shou University Kaohsiung Taiwan

3. Institute of Biomedical Informatics National Yang Ming Chiao Tung University Taipei Taiwan

4. Division of Translational Research, Department of Medical Research Taipei Veterans General Hospital Taipei Taiwan

Abstract

LINKED CONTENTThis article is linked to Hsu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17614 and https://doi.org/10.1111/apt.17630

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17644

Reference10 articles.

1. Editorial: mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—insights from a real‐world study;Mak L‐Y;Aliment Pharmacol Ther,2023

2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

3. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients

4. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population‐based cohort study

5. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm